ACE deletion polymorphism is associated with a high risk of non-infectious pulmonary complications after stem cell transplantation

International Journal of Hematology
Mitsuki MiyamotoKiyoshi Ando

Abstract

Non-infectious pulmonary complication (NIPC) is a serious adverse event for allogeneic hematopoietic stem cell transplantation (allo-HSCT) patients. NIPC includes both categories of lung complications: early onset idiopathic pneumonia syndrome (IPS) (onset <120 days) and late-onset non-infectious pulmonary complications (LONIPCs). Both categories have high mortality and morbidity rates, and critical treatments are not available. The renin-angiotensin system plays a critical role in pulmonary fibrosis. We, therefore, studied the relationship between angiotensin-converting enzyme gene (ACE) insertion/deletion polymorphisms and NIPC incidence in 149 consecutive allo-HSCT recipients. A total of 12.1 % (18/149) of these patients were diagnosed with NIPC (IPS, 3; LONIPCs, 15). Eight NIPC patients died from respiratory failure (mortality rate, 44.4 %). Peripheral blood stem cell transplantation was associated with a significantly higher incidence of NIPC than bone marrow transplantation and cord blood transplantation by univariate analysis (HR 3.13, P = 0.031). The serum ACE levels differed significantly according to the ACE insertion/deletion polymorphism. Patients with an ACE D/D genotype occurred at a significantly higher frequency...Continue Reading

References

Jun 1, 1993·The American Review of Respiratory Disease·J G ClarkH H Peavy
Apr 8, 1998·British Journal of Haematology·A PalmasM R Litzow
Nov 14, 1998·The American Journal of Physiology·B D UhalG Filippatos
Jan 5, 1999·American Journal of Respiratory and Critical Care Medicine·A TanP B Bitterman
Jun 14, 2000·American Journal of Respiratory and Critical Care Medicine·R P MarshallG J Laurent
Jul 13, 2000·American Journal of Physiology. Lung Cellular and Molecular Physiology·R WangB D Uhal
Dec 4, 2001·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·S AsciogluUNKNOWN Mycoses Study Group of the National Institute of Allergy and Infectious Diseases
Aug 13, 2002·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Gregory YanikKenneth R Cooke
May 20, 2003·American Journal of Physiology. Lung Cellular and Molecular Physiology·Richard P MarshallGeoffrey J Laurent
Oct 22, 2003·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Arkadiusz Z DudekDaniel J Weisdorf
Jun 21, 2007·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Satoshi YoshiharaShin Mineishi
Nov 10, 2009·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Jason W ChienSteven Z Pavletic
Mar 23, 2011·International Journal of Hematology·Chiaki NakasekoShinichiro Okamoto
May 3, 2011·American Journal of Respiratory and Critical Care Medicine·Angela Panoskaltsis-MortariUNKNOWN American Thoracic Society Committee on Idiopathic Pneumonia Syndrome

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.